Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea

被引:13
|
作者
Ahn, So-Hyeon [1 ,2 ]
Choi, Nam-Kyong [3 ,4 ]
Kim, Ye-Jee [1 ,2 ]
Seong, Jong-Mi [1 ,2 ]
Shin, Ju-Young [1 ,2 ]
Jung, Sun-Young [1 ,2 ]
Park, Byung-Joo [1 ,2 ]
机构
[1] Korea Inst Drug Safety & Risk Management, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul 110799, South Korea
[3] Seoul Natl Univ, Seoul Natl Univ Hosp, Div Clin Epidemiol, Med Res Collaborating Ctr,Coll Med, Seoul 110799, South Korea
[4] Seoul Natl Univ, Med Res Ctr, Seoul 110799, South Korea
关键词
Medication persistence; Dementia; Alzheimer type; Cholinesterase inhibitors; Pharmacoepidemiology; Elderly; DISEASE; DONEPEZIL; EFFICACY; THERAPY; SAFETY; COSTS;
D O I
10.1007/s12272-014-0500-8
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study examined 1-year persistency with cholinesterase inhibitors (ChEIs) for the treatment of elderly Alzheimer's dementia (AD) patients in Korea. Korean Health Insurance Review & Assessment Service database from January 2005 to June 2006 was used. Patients aged 65 or older with AD diagnosis who were first prescribed a ChEI were included. The 1-year persistence, persistency rate, and switching patterns during the follow-up period were identified. Mean time to drug discontinuation was analyzed, and persistency rates between different patient factors were compared. The 1-year persistency rate of newly treated 6,461 AD patients was 24.0 %, while 50 % of study patients discontinued treatment by 91 days from initiation. Persistency rates of female patients (22.8 %), patients in rural areas (12.7 %), and primary care (10.2 %) were relatively low (p < 0.001). Persistency rate differed between age groups (p < 0.001). Overall proportion of switching was 6.6 %. The 1-year persistency rate of ChEIs for AD patients in Korea did not reach those of previous researches in other countries. Patients less likely to remain on therapy should be especially monitored to optimize treatment persistence.
引用
收藏
页码:1255 / 1262
页数:8
相关论文
共 50 条
  • [31] CHOLINESTERASE INHIBITORS: A POPULATION-BASED ASSESSMENT OF RESOURCE UTILIZATION AND COSTS FOR PATIENTS WITH ALZHEIMER'S DEMENTIA
    Fong, R. K.
    Gill, S. S.
    Johnson, A. P.
    VALUE IN HEALTH, 2012, 15 (07) : A280 - A280
  • [32] Switching cholinesterase inhibitors in patients with Alzheimer's disease
    Emre, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 64 - 72
  • [33] ADHERENCE TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH ALZHEIMER'S DISEASE
    Blais, Lucie
    Kettani, Fatima-Zohra
    Perreault, Sylvie
    Leroux, Jean-Christophe
    Forget, Amelie
    Kergoat, Marie-Jeanne
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 (02) : 366 - 368
  • [34] Cholinesterase Inhibitors in the Treatment of Dementia
    Ellis, Jay M.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2005, 105 (03): : 145 - 158
  • [35] Cholinesterase inhibitors for agitation in dementia
    Wilkinson, D
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) : 1085 - 1085
  • [37] Cholinesterase inhibitors in the treatment of dementia
    Margallo-Lana, ML
    Ballard, C
    Morris, C
    Kay, D
    Tyrer, S
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (05) : 458 - 459
  • [38] Tolerability of memantine in combination with cholinesterase inhibitors in Alzheimer's disease and vascular dementia
    Hartmann, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S84 - S84
  • [39] Cholinesterase inhibitors for vascular dementia?
    Schneider, LS
    LANCET NEUROLOGY, 2003, 2 (11): : 658 - 659
  • [40] Methylphenidate augmentation of cholinesterase inhibitors for the treatment of apathy associated with Alzheimer's dementia
    Kim, J. J.
    Lim, H. K.
    Won, W. Y.
    Lee, C. U.
    Lee, C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 137 - 137